324 related items for PubMed ID: 33506028
1. CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.
Teh YM, Lim SK, Jusoh N, Osman K, Mualif SA.
Biomed Res Int; 2021; 2021():6671552. PubMed ID: 33506028
[Abstract] [Full Text] [Related]
2. The role of B7-1 in proteinuria of glomerular origin.
Novelli R, Benigni A, Remuzzi G.
Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
[Abstract] [Full Text] [Related]
3. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
Cara-Fuentes G, Venkatareddy M, Verma R, Segarra A, Cleuren AC, Martínez-Ramos A, Johnson RJ, Garg P.
Pediatr Nephrol; 2020 Oct; 35(10):1887-1896. PubMed ID: 32399663
[Abstract] [Full Text] [Related]
4. Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease.
Ahmed HM, Ezzat DA, Doudar NA, Adel M.
Iran J Kidney Dis; 2018 Mar; 12(2):107-111. PubMed ID: 29507273
[Abstract] [Full Text] [Related]
5. Urinary CD80: a biomarker for a favorable response to corticosteroids in minimal change disease.
Cara-Fuentes G, Lanaspa MA, Garcia GE, Banks M, Garin EH, Johnson RJ.
Pediatr Nephrol; 2018 Jul; 33(7):1101-1103. PubMed ID: 29492674
[Abstract] [Full Text] [Related]
6. CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood.
Eroglu FK, Orhan D, İnözü M, Duzova A, Gulhan B, Ozaltin F, Topaloglu R.
Pediatr Int; 2019 Dec; 61(12):1250-1256. PubMed ID: 31513327
[Abstract] [Full Text] [Related]
7. Upregulation of CD80 on glomerular podocytes plays an important role in development of proteinuria following pig-to-baboon xeno-renal transplantation - an experimental study.
Rivard CJ, Tanabe T, Lanaspa MA, Watanabe H, Nomura S, Andres-Hernando A, Garth K, Sekijima M, Ishimoto T, Ariyoshi Y, Garcia GE, Shah J, Lennan B, Tasaki M, Pomposelli T, Shimizu A, Sachs DH, Johnson RJ, Yamada K.
Transpl Int; 2018 Oct; 31(10):1164-1177. PubMed ID: 29722117
[Abstract] [Full Text] [Related]
8. Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes.
Ishimoto T, Cara-Fuentes G, Wang H, Shimada M, Wasserfall CH, Winter WE, Rivard CJ, Araya CE, Saleem MA, Mathieson PW, Johnson RJ, Garin EH.
Pediatr Nephrol; 2013 Sep; 28(9):1803-12. PubMed ID: 23689904
[Abstract] [Full Text] [Related]
9. Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome.
Mishra OP, Kumar R, Narayan G, Srivastava P, Abhinay A, Prasad R, Singh A, Batra VV.
Pediatr Nephrol; 2017 Aug; 32(8):1355-1361. PubMed ID: 28210837
[Abstract] [Full Text] [Related]
10. Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis?
Cara-Fuentes G, Wasserfall CH, Wang H, Johnson RJ, Garin EH.
Pediatr Nephrol; 2014 Dec; 29(12):2333-40. PubMed ID: 25017621
[Abstract] [Full Text] [Related]
11. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G.
Am J Physiol Renal Physiol; 2016 Mar 01; 310(5):F335-41. PubMed ID: 26697986
[Abstract] [Full Text] [Related]
12. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.
Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ.
Pediatr Nephrol; 2015 Mar 01; 30(3):469-77. PubMed ID: 25239302
[Abstract] [Full Text] [Related]
13. [New insight in pathogenesis of podocyte disfunction in minimal change disease].
Liu S, Chen J.
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 Mar 01; 45(2):214-8. PubMed ID: 27273997
[Abstract] [Full Text] [Related]
14. The utility of urinary CD80 as a diagnostic marker in patients with renal diseases.
Minamikawa S, Nozu K, Maeta S, Yamamura T, Nakanishi K, Fujimura J, Horinouchi T, Nagano C, Sakakibara N, Nagase H, Shima H, Noda K, Ninchoji T, Kaito H, Iijima K.
Sci Rep; 2018 Nov 23; 8(1):17322. PubMed ID: 30470792
[Abstract] [Full Text] [Related]
15. Minimal change disease: a "two-hit" podocyte immune disorder?
Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH.
Pediatr Nephrol; 2011 Apr 23; 26(4):645-9. PubMed ID: 21052729
[Abstract] [Full Text] [Related]
16. Urinary CD80 excretion increases in idiopathic minimal-change disease.
Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ.
J Am Soc Nephrol; 2009 Feb 23; 20(2):260-6. PubMed ID: 19056875
[Abstract] [Full Text] [Related]
17. Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells.
Webendörfer M, Reinhard L, Stahl RAK, Wiech T, Mittrücker HW, Harendza S, Hoxha E.
Front Immunol; 2020 Feb 23; 11():586012. PubMed ID: 33628202
[Abstract] [Full Text] [Related]
18. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.
Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, Johnson RJ.
Kidney Int; 2010 Aug 23; 78(3):296-302. PubMed ID: 20485332
[Abstract] [Full Text] [Related]
19. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
Hansrivijit P, Puthenpura MM, Ghahramani N.
Clin Nephrol; 2020 Sep 23; 94(3):117-126. PubMed ID: 32589135
[Abstract] [Full Text] [Related]
20. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice.
Ishimoto T, Shimada M, Gabriela G, Kosugi T, Sato W, Lee PY, Lanaspa MA, Rivard C, Maruyama S, Garin EH, Johnson RJ.
Nephrol Dial Transplant; 2013 Jun 23; 28(6):1439-46. PubMed ID: 23262434
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
